<?xml version='1.0' encoding='UTF-8'?>
<rss xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" version="2.0"><channel><title>ギリアドトピックス</title><link>https://www.gilead.com/ja-jp/news</link><description>ギリアドの最新トピック情報</description><docs>http://www.rssboard.org/rss-specification</docs><generator>python-feedgen</generator><language>ja</language><lastBuildDate>Sat, 29 Nov 2025 22:22:51 +0000</lastBuildDate><item><title>ギリアド、HIV流行終結を目指すコンソーシアム「HIV/AIDS GAP6」の特設サイトを公開</title><link>https://www.gilead.com/ja-jp/-/media/gileadjapan/pdfs/news-and-press/press-releases/2025/20251001_web_press-release_gap6-web-site-launch.pdf</link><description>ギリアド、HIV流行終結を目指すコンソーシアム「HIV/AIDS GAP6」の特設サイトを公開</description><guid isPermaLink="false">https://www.gilead.com/ja-jp/-/media/gileadjapan/pdfs/news-and-press/press-releases/2025/20251001_web_press-release_gap6-web-site-launch.pdf</guid></item><item><title>ギリアドとKite、CAR T細胞製品をより効率的、安定的に患者さんに届けるため、国内に自社拠点を開設</title><link>https://www.gilead.com/ja-jp/-/media/gileadjapan/pdfs/news-and-press/press-releases/2025/20251006_press_release_web_gilead_and_kite_open_new_facility_in_japan.pdf</link><description>ギリアドとKite、CAR T細胞製品をより効率的、安定的に患者さんに届けるため、国内に自社拠点を開設</description><guid isPermaLink="false">https://www.gilead.com/ja-jp/-/media/gileadjapan/pdfs/news-and-press/press-releases/2025/20251006_press_release_web_gilead_and_kite_open_new_facility_in_japan.pdf</guid></item><item><title>ギリアド、「HIV流行終結に向けた活動を支援する寄附プログラム」で3団体の活動を採択</title><link>https://www.gilead.com/ja-jp/-/media/gileadjapan/pdfs/news-and-press/press-releases/2025/20251028_web_press-release_hiv-grant-program-selection-results.pdf</link><description>ギリアド、「HIV流行終結に向けた活動を支援する寄附プログラム」で3団体の活動を採択</description><guid isPermaLink="false">https://www.gilead.com/ja-jp/-/media/gileadjapan/pdfs/news-and-press/press-releases/2025/20251028_web_press-release_hiv-grant-program-selection-results.pdf</guid></item><item><title>ギリアドとKite、ESMO 2025で発表される新データにより、がん治療を革新するための取り組みを強化</title><link>https://www.gilead.com/ja-jp/-/media/gileadjapan/pdfs/news-and-press/press-releases/2025/20251030_press-release_web_esmo_curtain_raiser.pdf</link><description>ギリアドとKite、ESMO 2025で発表される新データにより、がん治療を革新するための取り組みを強化</description><guid isPermaLink="false">https://www.gilead.com/ja-jp/-/media/gileadjapan/pdfs/news-and-press/press-releases/2025/20251030_press-release_web_esmo_curtain_raiser.pdf</guid></item><item><title>ギリアド、「CAR T細胞療法における地域格差解消のための寄附プログラム」について3団体の提案を採択</title><link>https://www.gilead.com/ja-jp/-/media/gileadjapan/pdfs/news-and-press/press-releases/2025/20251104_press_release_web_car-t-cell-therapy-grant-program-selection-results.pdf</link><description>ギリアド、「CAR T細胞療法における地域格差解消のための寄附プログラム」について3団体の提案を採択</description><guid isPermaLink="false">https://www.gilead.com/ja-jp/-/media/gileadjapan/pdfs/news-and-press/press-releases/2025/20251104_press_release_web_car-t-cell-therapy-grant-program-selection-results.pdf</guid></item><item><title>ASCENT-03試験：トロデルビ®、転移・再発トリプルネガティブ乳がんの一次治療において化学療法との比較で病勢進行や死亡のリスクを38%低減</title><link>https://www.gilead.com/ja-jp/-/media/gileadjapan/pdfs/news-and-press/press-releases/2025/20251106_press-release_web_esmo_ascent-03.pdf</link><description>ASCENT-03試験：トロデルビ®、転移・再発トリプルネガティブ乳がんの一次治療において化学療法との比較で病勢進行や死亡のリスクを38%低減</description><guid isPermaLink="false">https://www.gilead.com/ja-jp/-/media/gileadjapan/pdfs/news-and-press/press-releases/2025/20251106_press-release_web_esmo_ascent-03.pdf</guid></item><item><title>ギリアド、2025年第3四半期業績を発表</title><link>https://www.gilead.com/ja-jp/-/media/gileadjapan/pdfs/news-and-press/press-releases/2025/20251113_web_press-release_gilead-sciences-announces-third-quarter-2025-financial-results.pdf</link><description>ギリアド、2025年第3四半期業績を発表</description><guid isPermaLink="false">https://www.gilead.com/ja-jp/-/media/gileadjapan/pdfs/news-and-press/press-releases/2025/20251113_web_press-release_gilead-sciences-announces-third-quarter-2025-financial-results.pdf</guid></item><item><title>ギリアド、「PRIDE指標2025」の「レインボー」認定を初めて獲得  「ゴールド」認定は3年連続で取得</title><link>https://www.gilead.com/ja-jp/-/media/gileadjapan/pdfs/news-and-press/press-releases/2025/20251117_web_press_release_pride-index-2025_2.pdf</link><description>ギリアド、「PRIDE指標2025」の「レインボー」認定を初めて獲得  「ゴールド」認定は3年連続で取得</description><guid isPermaLink="false">https://www.gilead.com/ja-jp/-/media/gileadjapan/pdfs/news-and-press/press-releases/2025/20251117_web_press_release_pride-index-2025_2.pdf</guid></item><item><title>ギリアドとKite、革新的な血液がん治療の進捗状況を示す新たな細胞療法のデータをASH 2025で発表</title><link>https://www.gilead.com/ja-jp/-/media/gileadjapan/pdfs/news-and-press/press-releases/2025/20251125_press-release_web_ash_2025.pdf</link><description>ギリアドとKite、革新的な血液がん治療の進捗状況を示す新たな細胞療法のデータをASH 2025で発表</description><guid isPermaLink="false">https://www.gilead.com/ja-jp/-/media/gileadjapan/pdfs/news-and-press/press-releases/2025/20251125_press-release_web_ash_2025.pdf</guid></item><item><title>ギリアド、第III相ASCENT-07試験の最新データを発表</title><link>https://www.gilead.com/ja-jp/-/media/gileadjapan/pdfs/news-and-press/press-releases/2025/20251126_press-release_web_ascent-07.pdf</link><description>ギリアド、第III相ASCENT-07試験の最新データを発表</description><guid isPermaLink="false">https://www.gilead.com/ja-jp/-/media/gileadjapan/pdfs/news-and-press/press-releases/2025/20251126_press-release_web_ascent-07.pdf</guid></item></channel></rss>